CA-SCIENTIST.COM
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i® , the company’s new supplier pre-assessment program, has officially launched with the successful completion of an on-site assessment of Boca Biolistics’s biorepository facilities. VERIF.i was developed to help both sides of the Scientist.com marketplace. Pre-assessments help suppliers such as Boca Biolistics demonstrate their quality and capabilities, while helping pharma and biotech customers select regulated services in an accelerated manner with more confidence and less risk.
“We have always been confident in the quality of our facilities and the personnel that operate them,” stated Joseph Mauro, Chief Vision Officer at Boca Biolistics. “VERIF.i allows us to demonstrate our expertise to current and future clients of Scientist.com’s marketplace as well as to our existing clientele outside of the platform."
Boca Biolistics is a hybrid contract research organization (CRO) with an integrated life science biorepository, offering central laboratory testing as well as clinical trial services. The company procures human biospecimens from around the world for commercial product development and the advancement of precision medicine. VERIF.i enables Boca Biolistics and other suppliers of regulated research services to communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection.
“On-site assessments are expensive, resource intensive and time consuming for customers and suppliers,” stated Matt McLoughlin, Sr. VP of Categories and Compliance at Scientist.com. “VERIF.i standardizes and simplifies the process for both sides of the market. It enables suppliers to differentiate themselves from their peers while enabling customers to gain valuable, unbiased insight into a supplier’s facilities, personnel and processes."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About Boca Biolistics
Boca Biolistics is a hybrid CRO leveraging our vertically integrated model to build a life sciences biorepository with industry leading clinical and molecular data sets. Our commercial biobank has >800,000 specimens available for use in R&D as well as clinical trials. Our CLIA/CAP accredited reference lab offers clinical testing as well as research testing services for diagnostic and pharma. Our CRO division provides end-to-end services for both diagnostic and biopharma clinical trials.
Visit bocabio.com to learn more.
Join us on our LinkedIn page.
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BitGo Holdings Announces Pricing of Initial Public Offering22.1.2026 03:38:00 CET | Press release
BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, announced today the pricing of its initial public offering of an aggregate of 11,821,595 shares of Class A common stock at a price to the public of $18.00 per share. The offering consists of 11,026,365 shares of Class A common stock being offered by BitGo and 795,230 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo has granted the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on January 22, 2026 under the ticker symbol "BTGO" and the offering is expected to close on January 23, 2026, subject to customary closin
Kioxia Selected in Clarivate Top 100 Global Innovators 202622.1.2026 02:30:00 CET | Press release
Kioxia Corporation has been named a Clarivate Top 100 Global Innovators 2026, an award given to the most innovative global companies by Clarivate Plc. This is the fifth time Kioxia has received this prestigious award in recognition of its accomplishment in intellectual property. The Clarivate Top 100 Global Innovators 2026 Awards were presented to the world’s most innovative companies and organizations, based on Clarivate’s proprietary analysis of intellectual property and patent trends. The methodology uses a model that measures innovation and focuses on consistent high performance and scale in innovativeness, where all ideas compete equally. Based on its mission of “uplifting the world with ‘memory,’” Kioxia will cultivate a new era of flash memory with its innovative technology to promote research and technology development that supports the increasing adoption of AI and the digital society of the future. Kioxia continues to protect and effectively utilize its intellectual property
Access Advance Closes 2025 with Record Quarter: Eight Major Licensees, 100% Renewal Rate, Litigations Resolved22.1.2026 02:00:00 CET | Press release
Access Advance LLC today announced the conclusion of an exceptional fourth quarter, with growth in all three main patent pools highlighted by the addition of eight major Licensees, a 100% renewal rate among HEVC Advance Licensees in good standing, and the resolution of multiple Licensor enforcement actions through pool licenses. The HEVC Advance Patent Pool welcomed 29 new Licensees, an 8% increase in total Licensees in just three months. The VVC Advance Patent Pool grew 40% with the signing of eight new Licensees, while the Advance VDP Pool added both a new Licensor and the first U.S.-based Licensee. Among the new Licensees joining Access Advance's programs were Hisense, Mercedes-Benz AG, Roku, Skyworth, Transsion, and Xiaomi in HEVC Advance; OPPO, vivo and Xiaomi in VVC Advance, and Roku in the VDP Pool. The quarter also saw the resolution of multiple Licensor-initiated litigations through licensing, with Hisense, Roku, and Transsion joining the HEVC Advance Patent Pool. Roku also be
IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 202621.1.2026 22:15:00 CET | Press release
IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2025 earnings results following the market close on Wednesday, Feb. 11, 2026. The management team will host a live webcast on Thursday, Feb. 12, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company’s management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 19, 2026 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and en
UAE Research Program for Rain Enhancement Science Announces Awardees of 6th Cycle Grants21.1.2026 21:17:00 CET | Press release
The UAE Research Program for Rain Enhancement Science (UAEREP), managed by the National Center of Meteorology (NCM), announced the awardees of its Sixth Cycle research grants. Each recipient will receive up to US$1.5 million over three years, with a maximum annual allocation of US$550,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121231610/en/ UAE Research Program for Rain Enhancement Science Announces Awardees of 6th Cycle Grants (Photo: AETOSWire) The Sixth Cycle awardees are Dr. Dixon Michael, Principal Radar Meteorologist and Software Engineer at Echo Science Works, USA, for “Advancing Cloud Seeding Science with Dual-Polarization Radar Signatures and AI”; Prof. Linda Zou, Adjunct Professor at Victoria University, Australia, for “AI-assisted Development and Optimization of Glaciogenic Cloud Seeding Materials”; and Dr. Oliver Branch, Senior Scientist at the University of Hohenheim, Germany, for “Rainfall Enhanceme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom